kabutan

Carna Biosciences, Inc.(4572) Summary

4572
TSE Growth
Carna Biosciences, Inc.
412
JPY
-21
(-4.85%)
Jan 29, 3:05 pm JST
2.69
USD
Jan 29, 1:05 am EST
Result
PTS
outside of trading hours
413
Jan 29, 3:05 pm JST
Summary Chart Historical News Financial Result
PER
PBR
9.13
Yield
ー%
Margin Trading Ratio
Stock Price
Jan 29, 2026
Opening Jan 29, 9:00 am
431 JPY 2.81 USD
Previous Close Jan 28
433 JPY 2.83 USD
High Jan 29, 9:00 am
431 JPY 2.81 USD
Low Jan 29, 12:36 pm
406 JPY 2.65 USD
Volume
190,900
Trading Value
0.08B JPY 0.52M USD
VWAP
413.82 JPY 2.7 USD
Minimum Trading Value
41,200 JPY 269 USD
Market Cap
7.89B JPY 0.05B USD
Number of Trades
383
Liquidity & Number of Trades
As of Jan 29, 2026
Liquidity
Slightly High
1-Year Average
410
1-Year High Dec 12, 2025
10,992
Margin Trading
Date Short Interest Long Margin Positions Ratio
Jan 23, 2026 0 1,939,500
Jan 16, 2026 0 1,867,400
Jan 9, 2026 0 1,844,000
Dec 26, 2025 0 1,720,500
Dec 19, 2025 58,900 1,913,100 32.48
Company Profile
Carna Biosciences, Inc. specializes in drug discovery support services, primarily focusing on the production and sale of kinase proteins and analysis outsourcing. The company is also expanding into drug discovery.
Sector
Pharmaceuticals
Carna Biosciences, Inc. offers a diverse range of products and services supporting early-stage drug discovery, including the manufacture and sale of kinase proteins, assay development, profiling and screening services, and cell-based assay services. The company's strength lies in its extensive lineup of kinase proteins and assay kits. Additionally, Carna Biosciences is focusing on in-house drug discovery with kinase inhibitors, advancing research and development of new drugs in key disease areas such as cancer and immune-inflammatory disorders. For cancer-related projects, the company plans to conduct studies up to Phase II trials at most, while for other diseases, it aims to carry out Phase I trials or preclinical studies before out-licensing to pharmaceutical companies.